At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP)
In Brief
A Phase 2 clinical trial evaluating Carboplatin, Cisplatin, and 2 other interventions for Laryngeal Squamous Cell Carcinoma and 2 related conditions. Active but no longer recruiting, targeting 28 participants across 1 site.
Detailed Summary
This phase II trial studies how well cisplatin, docetaxel, and pembrolizumab work in treating patients with stage II-III laryngeal cancer. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cisplatin, docetaxel, and pembrolizumab may help to control the disease.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given IV